The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

被引：0
|
作者：
Weber, Martin [1 ,2 ,3 ]
Kappos, Ludwig [4 ]
Hauser, Stephen [5 ]
Nicholas, Jacqueline [6 ]
Schneble, Hans-Martin [7 ]
Wang, Qing [7 ]
Giovannoni, Gavin [8 ]
Filippi, Massimo [9 ,10 ]
机构：
[1] Inst Neuropathol, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Gottingen, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Gottingen, Germany
[4] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[5] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA USA
[6] OhioHlth Multiple Sclerosis Clin, Columbus, OH USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Queen Mary Univ London, London, England
[9] IRCCS San Raffaele Sci Inst, Neurol Unit, Neurophysiol Serv, Neurorehabil Unit,Neuroimaging Res Unit,Div Neuro, Milan, Italy
[10] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P302/406
引用
收藏
页码：350 / 351
页数：2
相关论文
共 50 条
  • [1] The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: Long-term data from the Phase III OPERA and ORATORIO studies
    Hauser, Stephen
    Giovannoni, Gavin
    Filippi, Massimo
    Weber, Martin
    Montalban, Xavier
    Nicholas, Jacqueline
    Schneble, Hans-Martin
    Wang, Qing
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1052 - 1053
  • [2] Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies
    Mayer, Lori
    Kappos, Ludwig
    Racke, Michael K.
    Rammohan, Kottil
    Traboulsee, Anthony
    Hauser, Stephen L.
    Julian, Laura
    Kondgen, Harold
    Li, Carrie
    Napieralski, Julie
    Zheng, Hanzhe
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 236 - 243
  • [3] Long-term efficacy of ocrelizumab in the treatment of patients with multiple sclerosis - case reports
    Krzystanek, Ewa
    Brola, Waldemar
    Wnuk, Marcin
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 93 - 104
  • [4] Safety profile and adherence to treatment with ocrelizumab in multiple sclerosis - long-term observations
    Pokryszko-Dragan, Anna
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 105 - 110
  • [5] No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies
    Havrdova, Eva
    Hauser, Stephen
    Honeycutt, William
    Kappos, Ludwig
    Selmaj, Krzysztof
    Wolinsky, Jerry
    Belachew, Shibeshih
    Bernasconi, Corrado
    Buffels, Regine
    Garren, Hideki
    Wei, Wei
    Traboulsee, Anthony
    NEUROLOGY, 2017, 88
  • [6] Long-term effect of ocrelizumab on brain volume and lesion activity outcomes in patients with relapsing multiple sclerosis: Analysis of 10-year data from the OPERA trials
    Granziera, Cristina
    Kolind, Shannon
    Traboulsee, Anthony
    Hauser, Stephen
    Bonati, Ulrike
    Wang, Qing
    von Buren, Gisele
    Clayton, David
    Craveiro, Licinio
    Arnold, Douglas L.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 89 - 90
  • [7] Long-term reduction of relapse rate and confirmed disability progression after 7.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis in the OPERA OLE
    Giovannoni, G.
    Kappos, L.
    de Seze, J.
    Hauser, S. L.
    Bonati, U.
    Overell, J.
    Hahn, M.
    Prajapati, K.
    Wang, Q.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 606 - 607
  • [8] NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies
    Traboulsee, Anthony
    Giovannoni, Gavin
    Bar-Or, Amit
    Comi, Giancarlo
    Hartung, Hans-Peter
    Havrdova, Eva
    Kappos, Ludwig
    Lublin, Fred
    Selmaj, Krzysztof
    Han, Jian
    Julian, Laura
    Belachew, Shibeshih
    Hauser, Stephen L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 18 - 19
  • [9] Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive Multiple Sclerosis from the Phase III ORATORIO Study
    Kappos, L.
    Montalban, X.
    Hauser, S. L.
    Julian, L.
    Manfrini, M.
    Belachew, S.
    Model, F.
    Hubeaux, S.
    Bar-or, A.
    Wolinsky, J. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 431 - 431
  • [10] NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from OPERA I and OPERA II, phase III studies.
    Giovannoni, G.
    Arnold, D. L.
    Bar-Or, A.
    Comi, G.
    Hartung, H. -P.
    Havrdova, E.
    Kappos, L.
    Lublin, F.
    Selmaj, K.
    Traboulsee, A.
    Belachew, S.
    Han, J.
    Julian, L.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 837 - 838
12345